x

Search for a clinical trial

* (*) mandatory field

A Phase 1/2, Multicenter, Open-label Study to Assess Safety, Pharmacokinetics, and Preliminary Efficacy of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas -DE

  • Type of clinical trial : Drug clinical trial
  • Recruiting project : Yes
  • Status : Ongoing trial
  • Funding body(ies) :
  • Geographic coverage : Global
  • Sponsor : Celgene corporation
  • Website
    • Phase : I
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Charité - Universitätsmedizin Berlin
  • Charitéplatz 1
  • 10117 BERLIN
  • GERMANY
  • More information
  • Phone  : 49 (0)30 450 50
  • Fax  : -
  • Website
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Universitätsklinikum Münster
  • Albert-Schweitzer-Campus 1
  • 48149 MÜNSTER
  • GERMANY
  • More information
  • Phone  : 49 (0)251 83 48001
  • Fax  : -
  • Website
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Universität Leipzig
  • Ritterstraße 26
  • 04109 LEIPZIG
  • GERMANY
  • More information
  • Phone  : 49 (0)341 97 108
  • Fax  : 49 (0)341 97 30099
  • Website
  • Principal investigator of clinical trial

  • INFORMATION NOT PROVIDED
  • Universitätsklinikum Würzburg
  • Josef-Schneider-Str. 2
  • 97080 WÜRZBURG
  • GERMANY
  • More information
  • Phone  : 0049 931 2010
  • Fax  : -
Last update: October 2021

Additional information

The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.